Where does brentuximab vedotin fit into the management of patients with hodgkin lymphoma?

Current Hematologic Malignancy Reports

Volumn 7, Issue 3, 2012, Pages 179-185

  Goyal, Sagun D ^a   Bartlett, Nancy L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody drug conjugate; Brentuximab vedotin; CD30; Classical Hodgkin lymphoma; Neuropathy; Stem cell transplantation

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; DOXORUBICIN; GEMCITABINE; NAVELBINE; SGN 30;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CLASSICAL HODGKIN LYMPHOMA; DISEASE CONTROL; DRUG APPROVAL; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HODGKIN DISEASE; HUMAN; INFLAMMATORY CELL; LARGE CELL LYMPHOMA; LUNG INSUFFICIENCY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; REED STERNBERG CELL; SALVAGE THERAPY; SENSORY NEUROPATHY; STEM CELL TRANSPLANTATION; TREATMENT DURATION; TREATMENT FAILURE;

ANTIGENS, CD30; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; RETREATMENT; SALVAGE THERAPY; STEM CELL TRANSPLANTATION;

EID: 84865965711     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0126-1     Document Type: Article

References (19)

1. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12:1065-72.
2. Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. ASH Educ Program Book. 2008;2008:326-33.
3. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. ;363:1812-21. This phase I study demonstrated safety and efficacy of the every 3 week dosing schedule for brentuximab vedotin.
4. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal Phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012 epub. This phase II study demonstrated a high response rate for brentuximab vedotin in patients with heavily pretreated Hodgkin lymphoma. It showed highly durable remissions in the group of patients that achieved a complete response to therapy. The results from this study led to accelerated approval for brentuximab vedotin as salvage therapy for Hodgkin lymphoma.
5. Bartlett NL, Younes A, CarabasiMH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111:1848-54.
6. Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146:171-9.
7. Blum KA, Jung SH, Johnson JL, et al. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associatedwith an FcgammaRIIIa-158 V/F polymorphism. Ann Oncol. 2010;21:2246-54.
8. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A Phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18:248-55.
9. Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol. 1998;16:584-8.
10. Rule S, Tighe M, Davies S, Johnson S. Vinorelbine in the treatment of lymphoma. Hematol Oncol. 1998;16:101-5.
11. Venkatesh H, Di Bella N, Flynn TP, et al. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma. 2004;5:110-5.
12. Zinzani PL, Bendandi M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica. 2000;85:926-9.
13. Bartlett N, Grove L, Kennedy A, et al. Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: a case series, ASCO Annual Meeting Abstracts. 2010;28(15s):8062.
14. Foyil KV, Kennedy DA, Grove LE, et al. Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma. Leuk Lymphoma. 2011;53(3):506-7.
15. Forero-Torres A, Berryman RB, Advani RH, et al. Prolonged treatment with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL), ASH Annual Meeting Abstracts. 2011;118:3711
16. Chen R, Forman SJ, Palmer J, et al. Brentuximab vedotin (SGN-35) enables successful reduced intensity allogeneic hematopoietic cell transplantation in relapsed/refractory Hodgkin lymphoma. ASH Annual Meeting Abstracts. 2011;118:664.
17. Illidge T, Bouabdallah R, Chen RW, et al. Allogeneic transplant following brentuximab vedotin treatment in patients with relapsed or refractory CD30+ lymphomas. ASH Annual Meeting Abstracts. 2011;118:3091.
18. Younes A, Connors JM, Park SI, et al. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma, ASH Annual Meeting Abstracts. 2011;118:955.
19. Wagner-Johnston ND, Bartlett NL, et al. Progressive multifocal leukoencephalopathy (PML) in a patient with Hodgkin's lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2012; Mar 16 epub.